Eli Lilly and Co (BSP:LILY34)
R$ 130.52 -2.2 (-1.66%) Market Cap: 3.72 Til Enterprise Value: 3.84 Til PE Ratio: 113.84 PB Ratio: 56.38 GF Score: 73/100

Eli Lilly and Co at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 14, 2021 / 05:15PM GMT
Release Date Price: R$40.88 (-0.88%)
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

Great. Well, good afternoon, everybody, and thanks for joining us for the next session. I'm Matthew Harrison, one of the biopharma analysts here at Morgan Stanley. Very pleased to have Eli Lilly with us for the next session.

Before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures.

So pleased to have Mike Mason with us from Lilly, who runs Diabetes. And we've got a wide range of topics to talk about. So looking forward to it.

Questions & Answers

Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

Mike, I thought we could start with tirzepatide. Obviously, people are focused on the filing there and sort of next steps. So maybe you could just remind us where you are in terms of the filing and how that's progressing?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot